Novel Antibiotics for Gram-Negative Nosocomial Pneumonia
Antibiotics · 05.07.2024 · 13 (7) · 629
DOI: 10.3390/antibiotics13070629 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 05.07.2024. Verfasst von Maria Panagiota Almyroudi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Emergency Department, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Nosocomial pneumonia, including hospital-acquired pneumonia and ventilator-associated pneumonia, is the leading cause of death related to hospital-acquired infections among critically ill patients. A growing proportion of these cases are attributed to multi-drug-resistant (MDR-) Gram-negative bacteria (GNB). MDR-GNB pneumonia often leads to delayed appropriate treatment, prolonged hospital stays, and increased morbidity and mortality. This issue is compounded by the increased toxicity profiles of the conventional antibiotics required to treat MDR-GNB infections. In recent years, several novel antibiotics have been licensed for the treatment of GNB nosocomial pneumonia. These novel antibiotics are promising therapeutic options for treatment of nosocomial pneumonia by MDR pathogens with certain mechanisms of resistance. Still, antibiotic resistance remains an evolving global crisis, and resistance to novel antibiotics has started emerging, making their judicious use crucial to prolong their shelf-life. This article presents an up-to-date review of these novel antibiotics and their current role in the antimicrobial armamentarium. We critically present data for the pharmacokinetics/pharmacodynamics, the in vitro spectrum of antimicrobial activity and resistance, and in vivo data for their clinical and microbiological efficacy in trials. Where possible, available data are summarized specifically in patients with nosocomial pneumonia, as this cohort may exhibit ‘critical illness’ physiology that affects drug efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Emergency Department, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.
- Department of Critical Care Medicine, King's College Hospital NHS Foundation Trust, London SE5 9RS, UK.
- Department of Haematology, King's College London, London SE5 9RS, UK.
- Department of Critical Care, University Hospital of Ioannina, University of Ioannina, 45110 Ioannina, Greece.
- Pharmacy Department, King's College Hospital NHS Foundation Trust, London SE5 9RS, UK.
- School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Kings College London, London SE5 9RS, UK.
ORCID-Profile: Maria Panagiota Almyroudi, Ioannis Andrianopoulos, Georgios Papathanakos, Reena Mehta, Elizabeth Paramythiotou
Zitieren
APA
Almyroudi, M. P., Chang, A., Andrianopoulos, I., Papathanakos, G., Mehta, R., Paramythiotou, E., & Koulenti, D. (2024). Novel Antibiotics for Gram-Negative Nosocomial Pneumonia. Antibiotics, 13(7), 629. https://doi.org/10.3390/antibiotics13070629
Vancouver
Almyroudi MP, Chang A, Andrianopoulos I, Papathanakos G, Mehta R, Paramythiotou E, et al. Novel Antibiotics for Gram-Negative Nosocomial Pneumonia. Antibiotics. 2024;13(7):629. doi:10.3390/antibiotics13070629
BibTeX
@article{Almyroudi2024,
author = {Almyroudi, Maria Panagiota and Chang, Aina and Andrianopoulos, Ioannis and Papathanakos, Georgios and Mehta, Reena and Paramythiotou, Elizabeth and Koulenti, Despoina},
title = {Novel Antibiotics for Gram-Negative Nosocomial Pneumonia},
journal = {Antibiotics},
year = {2024},
volume = {13},
number = {7},
pages = {629},
doi = {10.3390/antibiotics13070629}
}
EUVIMED